Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TM2 domain-containing protein 2 (TM2D2) is a membrane protein containing a module structurally related to the seven transmembrane domain G protein-coupled receptor superfamily, though it is not itself a canonical GPCR[2][3]. It is homologous to beta-amyloid binding protein (BBP), but, unlike BBP, does not regulate responses to beta-amyloid peptide. TM2D2 may be involved in regulatory processes affecting cell death or proliferation, as suggested by its sequence features and some experimental parallels to TM2D family members implicated in Notch signaling regulation and neurodevelopment in model organisms[1][2][3]. Mutations in related TM2D genes (e.g., TM2D3) are associated with neurological deficits and neurodegenerative phenotypes in animal models, but there is limited direct evidence for TM2D2’s role in human disease outside of its association with a congenital myopathy[1][3]. It is not currently an established therapeutic target and no drugs or biomarkers are known for this protein.
Not established; no drugs currently target this protein specifically
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TM2 domain-containing protein 2 (TM2D2).